Skip to main content

Table 3 Summary of DNA methylation biomarkers in melanoma

From: Aberrant DNA methylation in melanoma: biomarker and therapeutic opportunities

Methylated gene(s)

Methylation association

Hazard ratioa

Reporting study

WIF1, TFPI2, RASSF1A and SOCS1

Advanced clinical stage

[34]

17-gene (see text)

Overall survival

2.41 (1.02–5.7)

[120]

RASSF1A, RAR-beta2, MGMT

Shorter overall survival

2.38 (1.1–4.8)

[117]

KIT, DSP, HCK, IL18

Shorter overall survival

[45]

HOXD9

Shorter overall survival

2.7 (1.1–6.5)

[49]

LINE-1

Shorter overall survival

2.63 (1.2–5.6)

[110]

MINT31

Longer overall survival

0.237 (not reported)

[34]

TFPI2

Presence of metastases

[172]

PTEN

Shorter overall survival

3.76 (1.2–11.1)

[14, 22]

MGMT

Response to therapy

-

[113]

Longer progression-free survival

2.17 (1.3–3.5)

TSLC1

Progression-free survival

-

[112]

RASSF1A

Resistance to therapy

0.21 (0.1–0.9)

[117]

ESR1

Shorter overall survival

2.31 (1.4–5.5)

[161]

Shorter progression free survival

2.64 (1.3–5.1)

p73

Sensitivity to therapy

[173]

  1. aWhere applicable, with 95% confidence interval in parenthesis